PharmaMar ibex35

Pharmamar Sousa

“Plitidepsin, The Most Powerful Antiviral, Has Been Shown To Be Effective Against The Coronavirus”

Pedro A. Muñoz | PharmaMar has just announced positive results for its APLICOV trial with Aplidin against COVID-19. This antiviral achieves the primary safety objective and the secondary efficacy goal, as well as a significant reduction in viral load and C-reactive protein (CRP) in hospitalized patients. A few days before this news, the company’s president, José María Fernández Sousa-Faro, gave an interview to The Corner.


PharmaMar Debuts This Week In An Ibex With 34 Stocks

On Monday, PharmaMar joined the Ibex 35, the main Spanish stock market index. It will will be composed of 34 stocks until October 19th, following the exclusion of MásMóvil after Lorca Telecom Bidco’s takeover bid. The Ibex 35’s Technical Advisory Committee unexpectedly announced on 10 September that PharmaMar would replace Ence in that index. Since then, the company’s share price has risen by more than 17% to 103.8 euros at last Friday’s close, recovering its July levels.